Last reviewed · How we verify
Busulfan preconditioning
At a glance
| Generic name | Busulfan preconditioning |
|---|---|
| Also known as | Busulfex |
| Sponsor | Shanghai Public Health Clinical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma (PHASE2)
- Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL (NA)
- Allo-HSCT vs ASCT in Adult T-LBL (NA)
- Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR (PHASE3)
- RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT (PHASE2)
- RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT (PHASE2)
- Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection (PHASE1, PHASE2)
- Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Busulfan preconditioning CI brief — competitive landscape report
- Busulfan preconditioning updates RSS · CI watch RSS
- Shanghai Public Health Clinical Center portfolio CI